Halozyme Therapeutics, Inc.
HALONASDAQHealthcare● Active
$70.73
$-0.80(-1.12%)
Market Cap$8.4B
P/E Ratio—
52W High$82.22
52W Low$51.06
Halozyme Therapeutics, Inc.（HALO）· 现金流量表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · HALO · 截至 2026-06-10
财务报表
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.32B | $0.44B | $0.28B | $0.20B | $0.40B |
| Depreciation & Amort. | $0.09B | $0.09B | $0.08B | $0.06B | $0.01B |
| Stock-Based Comp. | $0.05B | $0.04B | $0.04B | $0.02B | $0.02B |
| Change in Working Capital | ($0.15B) | ($0.14B) | ($0.04B) | ($0.11B) | $0.00B |
| Net Cash from Operations | $0.65B | $0.48B | $0.39B | $0.24B | $0.30B |
| Investing Activities | |||||
| Capital Expenditure | ($0.01B) | ($0.01B) | ($0.02B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.25B) | $0.00B | ($0.29B) | $0.00B | $0.00B |
| Sales of Investments | $0.72B | $0.00B | $0.21B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.55B) | ($0.26B) | ($0.10B) | ($0.49B) | ($0.41B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.34B) | ($0.25B) | ($0.40B) | ($0.20B) | ($0.35B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.24B | $0.00B | ($0.01B) | $0.62B | $0.42B |
| Net Cash from Financing | ($0.09B) | ($0.22B) | ($0.41B) | $0.36B | $0.08B |
| Free Cash Flow | |||||
| Free Cash Flow | $0.64B | $0.47B | $0.37B | $0.24B | $0.30B |
| FCF Margin %(computed) | 46.15% | 46.13% | 45.01% | 35.65% | 67.22% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-10 · USD · B
深入了解Halozyme Therapeutics, Inc.
关于Halozyme Therapeutics, Inc.（HALO）现金流量表
Halozyme Therapeutics, Inc. 2025财年经营活动现金流$0.65B，自由现金流$0.64B（FCF利润率46.15%），资本支出($0.01B)。
常见问题
HALO · 4 问Halozyme Therapeutics, Inc. 2025财年自由现金流$0.64B，同比up37.6%。
HALO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10